It looks like the biopharmaceutical shopping spree to acquire assets has eased off. The number of completed mergers and acquisitions in the biopharma industry disclosing financial details, recorded by BioWorld Snapshots, in the first half of this year was 31, which was 35 percent below the number of M&As completed for the same period last year. Total deal value was approximately $60.5 billion, less than half of the $158 billion total deal value in the same period of 2015.